Point32Health is offering a reminder pertaining to our biosimilar strategy for medical oncology drugs — specifically those in the trastuzumab drug class.
The preferred trastuzumab biosimilars for Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct, Tufts Health Together, and Tufts Health RITogether are Kanjinti and Trazimera.
As a reminder, prior authorization is required for all non-preferred trastuzumab products, which include Herceptin, Herceptin Hylecta, Ogivri, Herzuma, and Ontruzant.
For complete details, please refer to the following guidelines:
- Tufts Health Plan Trastuzumab
- Medicare Part B Step Therapy
- For Harvard Pilgrim’s commercial clinical criteria for Trastuzumab (and other) products, refer to the Harvard Pilgrim Prior Authorization Policies page on OncoHealth’s website.
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer